Medikamentöse Neuroprotektion in der Vestibularisschwannomchirurgie

Scheller, Christian; Herzfeld, Eva; Strauß, Christian

doi:10.1007/s00106-017-0386-0

HNO

2017

DOI: 10.1007/s00106-017-0386-0

|View full text |Cite

Medikamentöse Neuroprotektion in der Vestibularisschwannomchirurgie

Christian Scheller¹,

Eva Herzfeld²,

Christian Strauß³

Abstract: Prophylactic nimodipine can be recommended in VS surgery in patients with good preoperative hearing. The effect mechanisms of nimodipine and modifications to prophylaxis should be clarified in basic research.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

2022

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Management des Vestibularisschwannoms

Schulz¹,

Eßer²,

Rosahl³

et al. 2018

Laryngo-Rhino-Otol

View full text Add to dashboard Cite

ZusammenfassungPrimäres Ziel der Behandlungsstrategie von Vestibularisschwannomen ist der Erhalt bzw. die Optimierung der Lebensqualität unter bestmöglicher Erhaltung der Nervenfunktionen. Einfluss auf das Management von Vestibularisschwannomen haben in erster Linie Tumorgröße, Tumorlage, Wachstumstendenz, Alter und Komorbiditäten sowie audiovestibuläre Symptome, d. h. Gleichgewichts- und Hörstörungen.

show abstract

Management des Vestibularisschwannoms

Schulz¹,

Eßer²,

Rosahl³

et al. 2018

Laryngo-Rhino-Otol

View full text Add to dashboard Cite

show abstract

Nimodipine Treatment Protects Auditory Hair Cells from Cisplatin-Induced Cell Death Accompanied by Upregulation of LMO4

Fritzsche

Strauß

Scheller

et al. 2022

IJMS

View full text Add to dashboard Cite

Ototoxicity is one of the main dose-limiting side effects of cisplatin chemotherapy and impairs the quality of life of tumor patients dramatically. Since there is currently no established standard therapy targeting hearing loss in cisplatin treatment, the aim of this study was to investigate the effect of nimodipine and its role in cell survival in cisplatin-associated hearing cell damage. To determine the cytotoxic effect, the cell death rate was measured using undifferentiated and differentiated UB/OC−1 and UB/OC−2 cells, after nimodipine pre-treatment and stress induction by cisplatin. Furthermore, immunoblot analysis and intracellular calcium measurement were performed to investigate anti-apoptotic signaling, which was associated with a reduced cytotoxic effect after nimodipine pre-treatment. Cisplatin’s cytotoxic effect was significantly attenuated by nimodipine up to 61%. In addition, nimodipine pre-treatment counteracted the reduction in LIM Domain Only 4 (LMO4) by cisplatin, which was associated with increased activation of Ak strain transforming/protein kinase B (Akt), cAMP response element-binding protein (CREB), and signal transducers and activators of transcription 3 (Stat3). Thus, nimodipine presents a potentially well-tolerated substance against the ototoxicity of cisplatin, which could result in a significant improvement in patients’ quality of life.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Medikamentöse Neuroprotektion in der Vestibularisschwannomchirurgie

Abstract: Prophylactic nimodipine can be recommended in VS surgery in patients with good preoperative hearing. The effect mechanisms of nimodipine and modifications to prophylaxis should be clarified in basic research.

Cited by 2 publications

References 30 publications

Management des Vestibularisschwannoms

Management des Vestibularisschwannoms

Nimodipine Treatment Protects Auditory Hair Cells from Cisplatin-Induced Cell Death Accompanied by Upregulation of LMO4

Contact Info

Product

Resources

About